Monash IVF GroupMNIVF 78 3-Year ROIIC % is 9.67 as of Jun. 2025, which is 1485% above its 10-year median of 0.61. GuruFocus rates MNIVF with a GF Score™ of 78/100 and a GF Value™ of $0.79. The stock has 7 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Monash IVF Group ranks better than 57.35% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Monash IVF Group's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 9.67%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Monash IVF Group's 3-Year ROIIC % or its related term are showing as below:
MNIVF's 3-Year ROIIC % is ranked better than 57.35% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.125
vs MNIVF: 9.67
Monash IVF Group (OTCPK:MNIVF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Monash IVF Group 3-Year ROIIC % Related Terms
Monash IVF Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Monash IVF Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MNIVF vs TMO, DHR, IDXX: 3-Year ROIIC % Comparison
For the Diagnostics & Research subindustry, Monash IVF Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monash IVF Group 3-Year ROIIC % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Monash IVF Group's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Monash IVF Group (MNIVF) has a 3-Year ROIIC % of 9.67 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Monash IVF Group and its competitors. This is 1485% above median its historical median of 0.61. According to the industry distribution chart, Monash IVF Group ranks #87 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 42.6%.
Is Monash IVF Group's 3-Year ROIIC % too high?
Monash IVF Group's current 3-Year ROIIC % of 9.67 is 1485% above median its 10-year median of 0.61. The Medical Diagnostics & Research industry median 3-Year ROIIC % is 0.13. Monash IVF Group's value of 9.67 is 7636% above this industry median. Based on the distribution chart, Monash IVF Group ranks #87 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Monash IVF Group has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's 3-Year ROIIC % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #87 out of 204 companies for 3-Year ROIIC %. This puts Monash IVF Group in the upper half of its industry. The industry median 3-Year ROIIC % is 0.13. Monash IVF Group's value of 9.67 is 7636% above this benchmark. While the company's 10-year median is 0.61 vs. the industry median of 0.13, Monash IVF Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Diagnostics & Research company?
The median 3-Year ROIIC % among Medical Diagnostics & Research companies is 0.13, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monash IVF Group's current 3-Year ROIIC % of 9.67 is 7636% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Monash IVF Group and its competitors. For the Medical Diagnostics & Research industry, the median 3-Year ROIIC % is 0.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monash IVF Group's current 3-Year ROIIC % is 9.67, which is 1485% above median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Monash IVF Group (MNIVF) has a current 3-Year ROIIC % of 9.67. The stock's GF Value™ is $0.79, compared to a current price of $0.40 — trading 49.4% below its estimated fair value. The current 3-Year ROIIC % is 9.67, which is 1485% above median its 10-year median of 0.61 and 7636% above the Medical Diagnostics & Research industry median of 0.13. Monash IVF Group's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Monash IVF Group (MNIVF), the current 3-Year ROIIC % is 9.67 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (MNIVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of $0.40 is trading 49.4% below its estimated GF Value™ of $0.79.
Key valuation signals for MNIVF:
3-Year ROIIC %: 9.67 (1485% above median its 10-year median of 0.61)
GF Value™: $0.79 vs. price of $0.40 (49.4% below fair value)
Industry Position: 7636% above the Medical Diagnostics & Research median (#87 of 204)
No single metric tells the full story. See the MNIVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
78GF Score
Get the complete analysis for MNIVF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNIVF has been successfully added to your 
